KaloBios Initiates Phase 1/2 Trial Of Humaneered Monoclonal Antibody KB001 For Treatment Of Pseudomonas Infections In Mechanically Ventilated Patien
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered?, high-affinity antibody fragment that KaloBios is developing for the treatment of Pseudomonas aeruginosa infections.
More: continued here